Idiotypic cancer vaccine data

GZTC observed tumor-specific immune responses in 4 of 5 patients treated in a Phase I

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE